Laurie H. Sehn - Publications, H-index & Citations

Laurie H. Sehn

University of British Columbia

82H指数

658论文数

3.0W被引数

收录论文 91

发表时间

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial 塔fasitamab、lenalidomide和阿利霉素在复发或难治性滤泡性淋巴瘤（inMIND）中的研究：一项全球性、III期、随机对照试验

The Lancet

IF97.3

2025-12-05

PREAI

Laurie H Sehn; Kai Hübel; Stefano Luminari; Christian W Scholz; Antonio Salar; Shankara Paneesha; Björn Engelbrekt Wahlin; Panayiotis Panayiotidis; Hui-Peng Lee; Ana Jiménez-Ubieto; Juan-Manuel Sancho; Tae Min Kim; Eva Domingo Domenech; Takahiro Kumode; Christina Poh; Catherine Thieblemont; Dries Deeren; Edwin de Wit; Michael Arbushites; Irene Vassallo

Immunogenicity and safety of third, fourth and subsequent COVID-19 vaccine doses in recipients of hematopoietic cell transplantation and cellular therapy 造血细胞移植和细胞治疗受者接种第三、第四及后续COVID-19疫苗剂量的免疫原性和安全性

Transplantation and Cellular Therapy

IF4.4

2025-11-08

PREAI

C. Arianne Buchan; Gerard Agbayani; Katrina Hueniken; Abi Vijenthira; Michael Sebag; Peng Wang; Lisa K. Hicks; Annette E. Hay; Sarit Assouline; Graeme Fraser; Amaris Balitsky; Joy Mangel; Carolyn Owen; Anthony Reiman; Laurie Sehn; Heather Sutherland; Tinghua Zhang; Corey Arnold; Allison M. Wilkin; Tamara Leite; Erinn McCarthy; Angela M Crawley; Marc-Andre Langlois; Christopher Bredeson; Natasha Kekre; David Allan; Curtis Cooper; Sita Bhella

Retreatment with R-CHOP-like Therapy in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma 弥漫性大B细胞淋巴瘤晚期复发患者接受R-CHOP样疗法再治疗

Blood Advances

IF7.1

2025-11-01

OAAI

Jean-Nicolas Champagne; Diego Villa; Alina S. Gerrie; Christopher P. Venner; Graham W. Slack; Pedro Farinha; Jeffrey W. Craig; Laura K. Hilton; Kerry J. Savage; David W. Scott; Laurie H. Sehn

Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology 在高MYC/BCL2易位的弥漫大B细胞淋巴瘤中，进行剂量调整的EPOCH-R方案的群体推广，该淋巴瘤具有DLBCL形态。

Blood Advances

IF7.1

2025-10-17

OAAI

Waleed Alduaij; Laurie H. Sehn; Jean-Nicolas Champagne; Brett Collinge; Susana Ben-Neriah; Aixiang Jiang; Laura K Hilton; Merrill Boyle; Barbara Meissner; Graham W. Slack; Pedro Farinha; Jeffrey W Craig; Kerry J. Savage; Diego Villa; Alina S. Gerrie; Ciara L. Freeman; Andrew J. Mungall; Christian Steidl; David W. Scott

Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?复发性和难治性滤泡性淋巴瘤的治疗：哪种治疗适用于哪种患者以及哪个治疗线？

Blood

IF23.1

2025-08-19

PREAI

Carla Casulo; Laurie H. Sehn

Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignancies 多剂量SARS-CoV-2疫苗接种在血液恶性肿瘤患者中的增量免疫原性

British Journal of Haematology

IF3.8

2025-07-30

OAAI

Abi Vijenthira; Sita Bhella; Katrina Hueniken; Allison M. Wilkin; Michael Sebag; Peng Wang; Lisa K. Hicks; Annette E. Hay; Sarit Assouline; Amaris Balitsky; Graeme Fraser; Joy Mangel; Carolyn Owen; Anthony Reiman; Laurie Sehn; Heather Sutherland; Corey Arnold; Tamara Leite; Erinn McCarthy; Angela Crawley; Curtis Cooper; Marc-Andre Langlois; C. Arianne Buchan; VIP Study Investigators

Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial Axicabtagene ciloleucel与加拿大标准护理方案在复发或难治性大B细胞淋巴瘤患者中的比较：ZUMA-7试验的成本效益分析

JOURNAL OF MEDICAL ECONOMICS

IF3

2025-05-09

OAAI

John Kuruvilla; Laurie H. Sehn; Sydney Whitney; Anik R. Patel; Heather Cameron; Geoffrey G. J. Reid

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada 加拿大弥漫性大B细胞淋巴瘤治疗中双特异性抗体的优化使用

current oncology reports

IF3.4

2025-02-28

OAAI

Fleury, Isabelle; Macdonald, David; Shafey, Mona; Christofides, Anna; Sehn, Laurie H.

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)Tafasitamab 联合 Lenalidomide 和 Rituximab 治疗复发或难治性滤泡性淋巴瘤：来自一项 3 期研究（inMIND）的结果

BLOOD

IF23.1

2024-11-25

PREAI

Sehn, Laurie H.; Luminari, Stefano; Scholz, Christian W.; Huebel, Kai; Salar, Antonio; Paneesha, Shankara; Wahlin, Bjorn E.; Panayiotidis, Panayiotis; Lee, Hui-Peng; Ubieto, Ana Jimenez; Sancho, Juan-Manuel; Kim, Tae Min; Domenech, Eva Domingo; Kumode, Takahiro; Poh, Christina; Thieblemont, Catherine; Deeren, Dries; de Wit, Edwin; Arbushites, Michael; Casadebaig, Marie-Laure; Trneny, Marek

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma Mosunetuzumab单药治疗在重度预治疗复发或难治性套细胞淋巴瘤患者中显示出令人鼓舞的疗效和可管理的安全性。

BLOOD

IF23.1

2024-11-05

PREAI

Budde, Elizabeth; Matasar, Matthew; Sehn, Laurie H.; Assouline, Sarit E.; Kuruvilla, John; Flinn, Ian W.; Yoon, Sung-Soo; Bosch, Francesc; Greenwald, Daniel; Gutierrez, Norma C.; Tzachanis, Dimitrios; Marlton, Paula; Mcguirt, Delaney; Yin, Shen; Wei, Michael C.; Kwan, Antonia; Tracy, Samuel; Penuel, Elicia; Bartlett, Nancy L.

Retreatment with R-CHOP-like Therapy in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma (DLBCL)对晚期复发的弥漫性大B细胞淋巴瘤（DLBCL）患者进行R-CHOP样疗法再治疗

BLOOD

IF23.1

2024-11-05

PREAI

Champagne, Jean-Nicolas; Villa, Diego; Gerrie, Alina S.; Venner, Christopher P.; Slack, Graham W.; Farinha, Pedro; Craig, Jeffrey W.; Hilton, Laura; Savage, Kerry J.; Scott, David W.; Sehn, Laurie H.

A Novel Genetics-Based Classification of Advanced Follicular Lymphoma Identifies Prognostic Subgroups Following Bendamustine-Rituximab Immunochemotherapy 一种基于遗传学的晚期滤泡性淋巴瘤新型分类法，可识别接受 bendamustine-rituximab 免疫化疗后的预后亚组

BLOOD

IF23.1

2024-11-05

PREAI

Shaalan, Haya; Frontzek, Fabian; Freeman, Ciare Louise; Lytle, Andrew; Farinha, Pedro; Alduaij, Waleed; Ben-Neriah, Susana; Boyle, Merrill; Meissner, Barbara; Weng, Andrew P.; Sehn, Laurie H.; Steidl, Christian; Hilton, Laura; Scott, David W.; Morin, Ryan

Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras 慢性淋巴细胞白血病（CLL）和小淋巴细胞淋巴瘤（SLL）中的里希特转化（RT）：两个时代的比较

BLOOD

IF23.1

2024-11-05

PREAI

Champagne, Jean-Nicolas; Huang, Steven; Ramadan, Rayan; Venner, Christopher P.; Ramadan, Khaled; Sehn, Laurie H.; Savage, Kerry J.; Villa, Diego; Scott, David W.; Alduaij, Waleed; Toze, Cynthia L.; Gerrie, Alina S.

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥ 2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study Mosunetuzumab 在接受 ≥ 2 种既往治疗（包括有 POD24 病史者）的复发性和/或难治性滤泡性淋巴瘤患者中持续显示出具有临床意义的结果：一项关键性 II 期研究的 4 年随访结果

BLOOD

IF23.1

2024-11-05

PREAI

Shadman, Mazyar; Bartlett, Nancy L.; Matasar, Matthew; Schuster, Stephen J.; Assouline, Sarit E.; Sehn, Laurie H.; Kuruvilla, John; Giri, Pratyush; Cheah, Chan Y.; Dietrich, Sascha; Fay, Keith; Ku, Matthew; Nastoupil, Loretta; Wei, Michael C.; Yin, Shen; Ma, Connie Y.; Tracy, Samuel; Kwan, Antonia; Penuel, Elicia; Budde, L. Elizabeth

A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas 在患有晚期实体瘤和复发/难治性b细胞淋巴瘤的患者中，每日口服N-肉豆蔻酰转移酶抑制剂zelenirstat的首次人体I期试验

INVESTIGATIONAL NEW DRUGS

IF2.7

2024-06-05

OAAI

Sangha, Randeep; Jamal, Rahima; Spratlin, Jennifer; Kuruvilla, John; Sehn, Laurie H.; Beauchamp, Erwan; Weickert, Michael; Berthiaume, Luc G.; Mackey, John R.

Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-04-15

OAAI

Deng, Rong; Gibiansky, Leonid; Lu, Tong; Flowers, Christopher R.; Sehn, Laurie H.; Liu, Qi; Agarwal, Priya; Liao, Michael Z.; Dere, Randall; Lee, Calvin; Man, Gabriel; Hirata, Jamie; Li, Chunze; Miles, Dale

N-myristoylation inhibitor zelenirstat: New mechanistic insights and efficacy signals from a first in human phase I study

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Berthiaume, Luc Gerard; Beauchamp, Erwan; Gamma, Jay; Pain, Rony; Kostiuk, Morris A.; Cromwell, Christopher R.; Moussa, Eman W.; Julien, Olivier; Hubbard, Basil P.; Kuruvilla, John; Sehn, Laurie H.; Spratlin, Jennifer; Jamal, Rahima; Sangha, Randeep; Mackey, John R.

High-plex imaging and cellular neighborhood spatial analysis reveals multiple immune escape and suppression patterns in diffuse large B-cell lymphoma

LEUKEMIA

IF13.4

2024-04-04

OAAI

Reiss, David J.; Nakayama, Yumi; Weng, Andrew P.; Stokes, Matthew E.; Sehn, Laurie; Steidl, Christian; Scott, David W.; Huang, C. Chris; Gandhi, Anita K.

TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images - a multi-center generalizability analysis

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2024-02-08

PREAI

Yousefirizi, Fereshteh; Klyuzhin, Ivan S.; Hyun, Joo; Harsini, Sara; Tie, Xin; Shiri, Isaac; Shin, Muheon; Lee, Changhee; Cho, Steve Y.; Bradshaw, Tyler J.; Zaidi, Habib; Benard, Francois; Sehn, Laurie H.; Savage, Kerry J.; Steidl, Christian; Uribe, Carlos F.; Rahmim, Arman

Looking to achieve cure the first time around for DLBCL patients who are older and/or with co-morbidities

SEMINARS IN HEMATOLOGY

IF4.1

2023-11-01

PREAI

Brem, Elizabeth A.; Sehn, Laurie H.

研究方向